etidaligide
- Generic Name
- etidaligide
Study To Assess Safety And Efficacy Of AsiDNA In Combination With Olaparib In Participants With Recurrent Solid Tumors
Phase 1
Recruiting
- Conditions
- Metastatic Castration-resistant Prostate CancerRecurrent Epithelial Ovarian CancerBreast Cancer
- Interventions
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2023-03-31
- Lead Sponsor
- Valerio Therapeutics
- Target Recruit Count
- 115
- Registration Number
- NCT05700669
- Locations
- 🇺🇸
Next Oncology, San Antonio, Texas, United States
AsiDNA Children, Adolescents and Young Adults
- First Posted Date
- 2022-05-27
- Last Posted Date
- 2023-12-26
- Lead Sponsor
- Institut Curie
- Target Recruit Count
- 8
- Registration Number
- NCT05394558
- Locations
- 🇫🇷
Chu Nancy, Nancy, France
🇫🇷Chu Strasbourg, Strasbourg, France
🇫🇷Chu Toulouse, Toulouse, France
Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months
Phase 1
Terminated
- Conditions
- Ovarian Cancer
- Interventions
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 13
- Registration Number
- NCT04826198
- Locations
- 🇫🇷
CHU Jean Minjoz, Besançon, Besancon, France
🇫🇷Hospices civils de Lyon(CHU Lyon Sud), Pierre-Bénite, Lyon, France
🇫🇷Institut de Cancérologie de l'Ouest - St Herblain, Saint-Herblain, Nantes, France
AsiDNA (a DNA Repair Inhibitor) Administered IntraVenously in Advanced Solid Tumors
- First Posted Date
- 2018-07-06
- Last Posted Date
- 2022-03-24
- Lead Sponsor
- Valerio Therapeutics
- Target Recruit Count
- 33
- Registration Number
- NCT03579628
- Locations
- 🇧🇪
Institut Jules Bordet, Bruxelles, Belgium
🇧🇪Grand Hôpital de Charleroi, Charleroi, Belgium
🇫🇷Centre Leon Berard, Lyon, France
DNA Repair Inhibitor & Irradiation on Melanoma
- First Posted Date
- 2011-11-10
- Last Posted Date
- 2016-06-17
- Lead Sponsor
- DNA Therapeutics
- Target Recruit Count
- 27
- Registration Number
- NCT01469455
- Locations
- 🇫🇷
Hôpital hôtel-Dieu, Nantes, France
🇫🇷Hôpital de la Timone, Marseille, France
🇫🇷Centre Hospitalier Lyon Sud, Pierre-Bénite, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath